Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0024623 (gastric cancer)
 36,219 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

CA 19-9 and CEA serum levels were determined before and 7 days after surgery in 140 patients with gastrointestinal adenocarcinoma, and in 70 patients with gastrointestinal non neoplastic diseases. CA 19-9 test was shown to be positive in 37.9% of colorectal cancer, in 32.6% of gastric cancer and in 77.8% of pancreatic cancer. CA 19-9 test was also shown to be more sensitive for colonic cancer with respect to rectal cancer (40.9% vs. 23.5%). CA 19-9 test is more sensitive and specific than CEA. In particular, the reported results suggest the clinical value of CA 19-9 test in the diagnosis of pancreatic adenocarcinoma and as a suitable parameter in the follow-up of gastrointestinal cancer.
 ...
PMID:Clinical value of CA 19-9 (carbohydrate antigen) in gastrointestinal adenocarcinoma. 385 72

Eighteen patients with advanced metastatic gastrointestinal cancer (stomach cancer 7, liver cancer 9, pancreas cancer 2) were treated with human recombinant interferon alpha-2 at doses of 3.0 X 10(6)-10.0 X 10(6) IU/body i.m. daily or every second day, 30 X 10(6) IU/body for five consecutive days every four weeks, or 30 X 10(6) IU/body once weekly. No tumor response was demonstrated in any of our cases. Among fifteen evaluable cases, nine had stabilization of evaluable disease at four weeks, but six showed progressive disease. On the other hand, fever, chills, fatigue, anorexia, nausea and vomiting were pronounced. In two cases, CNS toxicities developed. In some instances, leukopenia, thrombocytopenia, decrease of hemoglobin content and elevation of transaminase were observed. According to these findings, single use of recombinant interferon alpha-2 at the dose schedule outlined above does not seem to be of use for the treatment of advanced gastrointestinal cancer.
 ...
PMID:[Phase II studies of interferon alpha-2 Sch 30500 in advanced gastrointestinal carcinoma]. 389 54

Cancer of the gastrointestinal tract represents a major international health problem. At the present time surgical resection for limited stages of disease represents the only treatment which can consistently provide long-term disease-free survival. Unfortunately, the majority of patients present with either microscopic metastatic disease in distant sites or advanced tumour growth which exceeds the limits of surgical resection. Relatively little progress has been made in the development of effective forms of non-surgical therapy. Gastric cancer, however, has been demonstrated to have greater sensitivity to forms of chemotherapy and radiation therapy than was previously appreciated. During the past decade, more effective forms of palliative therapy have been developed for patients with advanced disease, and approximately 15% of the cases with locally unresectable gastric cancer can now achieve long-term disease-free survival with combined forms of treatment. Unfortunately, similar progress has not been made in the management of pancreatic cancer or advanced colon cancer. The recent experience of the Gastrointestinal Tumor Study Group with the use of combined radiotherapy and chemotherapy for rectal cancer has demonstrated that improved disease-free survival can be achieved for patients with Dukes B and C disease. Overall, the current limited efficacy and considerable toxicity of conventional therapies strongly support the development of new approaches to the management of gastrointestinal cancer; this includes the exploitation of the recent progress that has been made in our understanding of cell proliferation and cell cycle control, and the importance of oncogenes and growth factors for regulation of these processes. Ultimately, our understanding of the molecular genetics of gastrointestinal cancer might allow for development of more effective means for both prevention and treatment at the molecular level.
 ...
PMID:Therapy of gastrointestinal cancer. 391 66

A follow-up survey of survivals (Oct. 1 '80 to May 1, '84) in a randomized controlled study (Aug. '79 to Sept. 30' 80) of lentinan in combination administration with chemotherapeutic agents such as 5FU + mitomycin C or tegafur on patients with advanced or recurrent gastrointestinal cancer has shown that lentinan has been effective in such cases with regard to the following facts: 1) A life span prolongation effect at the end-point has been observed with statistical significance in lentinan treated patients as was found in the phase III study. 2) Using the life table analysis method, a higher rate of survival has been observed in the lentinan treated group, especially in combination with tegafur for gastric cancer, clearly showing such high survival rates as 12.97% (P less than 0.05) at two years after, and 9.51% (P less than 0.05) and 3.81%, at three and four years after respectively, and for colorectal cancer, 9.10% and 4.55% at two years and three years after, respectively.
 ...
PMID:[Results of phase III study of lentinan]. 391 10

In recent years nutritional status gained greater attention as a surgical risk factor. This study analyzes the frequency of malnutrition in surgical patients with solid and operable tumors, the relation to the type of tumor and stage of the disease. In addition, the clinical value of the measurements carried out is discussed. The analysis was performed in 100 cancer patients (34 gastric cancer, 56 colorectal cancer, and 10 breast cancer). The nutritional assessment included individual dietary habits, ideal weight/height, triceps skinfold, arm muscle circumference, creatinine-height index, serum protein, albumin, prealbumin, cholinesterase, transferrin, total peripheral lymphocytes, and skin tests. The results were compared with international standards or normal plasma concentrations respectively. Most patients suffered from an alternation of the nutritional parameters indicating malnutrition, mostly Kwashiorkor-Marasmus Mix. Patients with gastrointestinal cancer, especially gastric cancer showed more often a decline of the nutritional status than patients with breast cancer. Malnutrition became more severe with advanced disease. The parameters examined revealed varying significance with respect to the assessment of the nutritional status. Some measurements showed little clinical importance; the reasons are discussed.
 ...
PMID:[Significance of the nutritional status of surgical patients]. 393 Sep 1

Gastric and pancreatic carcinomas are important worldwide health problems, typically diagnosed late in the disease process when symptoms of pain and weight loss signify the presence of locally advanced or metastatic tumor. During the past decade, new regimens of combination chemotherapy have, in general, produced increased response rates for patients with advanced gastric cancer, with evidence of improved survival in several controlled trials. For patients with locally advanced gastric cancer, combined-modality therapy has resulted in long-term survival for approximately 15% of cases. The role of adjuvant therapy is now being defined in several randomized control trials of doxorubicin-based chemotherapy regimens. The position of combination chemotherapy for advanced pancreatic carcinoma is less well defined, but present data favor a regimen of streptozotocin, mitomycin-C, and 5-fluorouracil. Combined-modality therapy has resulted in modest improvements in disease-free survival for patients with locally advanced and resected tumors. The search for more effective drugs for gastrointestinal cancer represents the highest priority in the development of treatment strategies for this important group of tumors.
 ...
PMID:The role of chemotherapy in the management of gastric and pancreatic carcinomas. 393 82

A phase II study on THP((2''R)-4'-0-Tetrahydropyranyladriamycin) was performed in 47 patients with advanced or recurrent gastrointestinal cancer through the cooperation of nine institutions in Hiroshima Prefecture from April 1982 to November 1984. THP was given by means of intravenous infusion and/or intraaortic infusion and the 47 cases were divided into two groups according to the method of administration: (A) 40-60 mg/body every 3 or 4 weeks, or (B) 30 mg/body every week. Among 24 evaluable cases, partial response (PR) was observed in two cases of recurrent metastatic lymph nodes in gastric cancer patients. The (A) method of administration was more effective than (B). Subjective side effects observed were appetite loss, nausea, vomiting and general fatigue, but these were not so severe. Leukocyte nadir occurred at the 1st or 2nd week of THP administration, but thrombocytes were not appreciably decreased.
 ...
PMID:[Phase II study of THP patients with gastrointestinal cancer]. 394 11

A phase II study of THP was performed in patients with advanced gastrointestinal cancer. The dose schedule was 25 to 40 mg/m2 i.v./cycle repeated every 3 to 4 weeks. One partial (PR) and one minor response (MR) were achieved in 16 evaluable patients with stomach cancer. A case of PR had previously been shown to be resistant to doxorubicin and a case of MR resistant to aclarubicin, respectively. No objective responses were observed in 19 evaluable patients with other tumor sites in the gastrointestinal tract. Forty-eight patients were evaluable for toxic effects. Leukopenia (less than 4 X 10(3)/mm3) occurred in 54% of the patients and was dose-limiting. Thrombocytopenia (less than 10 X 10(4)/mm3) was less frequently observed (13%) than leukopenia. However, no cumulative marrow suppression was observed in repeated courses of the therapy. Non-hematologic toxic effects consisted of gastrointestinal disturbances (23%), hair loss (10%), general malaise (8%), fever (6%), ECG changes (4%) and hepatic dysfunction (2%). Further trials with a high dose schedule (40 mg/m2, q 3-4 weeks) in good-risk patients are necessary to validate the antitumor activity of THP against advanced gastrointestinal cancer.
 ...
PMID:[Phase II study of (2''R)-4'-O-tetrahydropyranyldoxorubicin (THP) in patients with advanced gastrointestinal cancer--a report of the Tohoku THP Study Group]. 396 48

More than 30 years ago the association between growth hormone and certain tumors was established in animal studies. However, the few clinical studies on acromegalic patients usually failed to demonstrate such a link. It was only recently that acromegaly was found to be associated with other endocrine tumors and with a high incidence of colonic polyps. In a retrospective study we looked for gastrointestinal cancer in 48 acromegalic patients. Five were identified, two cancers of the stomach, two of the colon, and one of the rectum. One patient with stomach cancer and one with sigmoid carcinoma also had recurrent colonic polyps. It is postulated that in our patients, by some yet to be identified mechanisms, the incidence of gastrointestinal cancer is significantly increased in acromegaly.
 ...
PMID:Gastrointestinal tumors in acromegalic patients. 398 95

Historically coal mining populations have been reported to have elevated stomach cancer incidence rates. To identify which factors might be associated with cases who reside in these high risk areas, and specifically if particulate exposures from coal mining and coal utilization are associated with risk, a mining area of western Pennsylvania was defined for a retrospective case-control study. One hundred seventy-eight resident cases, identified from certificates of death, were compared to three controls: digestive cancer deaths, arteriosclerotic heart disease deaths, and neighborhood (living) controls. Controls were matched to each case on age, race, sex, and residence. Interviews were conducted during 1981 and 1982. Excess risks were shown for foreign born and eastern Europeans. Coal mining was not shown to be a risk factor for males, while an association was seen for female cases whose husbands were miners. Farming was a risk factor for males and females. Marked decreased risks were shown for gas heating and cooking fuels, with elevated risks for coal, wood and oil heating fuels, and wood cooking fuel. These findings are associated with lower socioeconomic status, and suggest environmental exposures or lifestyles that are directly and indirectly related to these risks factors. The marked inverse relationship between stomach cancer and use of gas heating and cooking fuel may be of important etiologic significance, especially in association with dietary changes. Further evaluation of prior use of various types of heating and cooking fuels needs to be considered especially using incident rather than case deaths.
 ...
PMID:A case-control study of stomach cancer in a coal mining region of Pennsylvania. 400 20


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>